Pozen Migraine Agent Advisory Cmte. Postponed; August Meeting Possible
This article was originally published in The Pink Sheet Daily
Executive Summary
Tardive dyskinesia risk with MT-100, the metoclopromide/naproxen combination product for migraine, continues to be the focus of a committee meeting, Pozen says. NDA filing for sumatriptan/naproxen migraine product Trexima is planned for the third quarter.
You may also be interested in...
Pozen Discontinues MT 100, Shifts Focus To Trexima NDA Filing
MT 100 U.S. development abandoned one day after FDA advisory committee recommends additional studies for the migraine product.
Pozen Discontinues MT 100, Shifts Focus To Trexima NDA Filing
MT 100 U.S. development abandoned one day after FDA advisory committee recommends additional studies for the migraine product.
Pozen MT-100 Migraine Combo Goes To Advisory Committee August 4
Tardive dyskinesia and cardiovascular issues are likely discussion topics for FDA’s Peripheral & Central Nervous System Drugs Advisory Committe. Treatment was to be reviewed by the committee in May but was postponed due to “scheduling conflicts.”